Welcure Drugs & Pharmaceuticals Ltd wins new Rs. 856 million (Rs. 85.6 crore) export-sourcing orders from Giant Exim & Ravina International

The order is in addition to recently securing Rs. 517 crore Global Sourcing Mandate with Thailand based Fortune Sagar Impex Company Limited

Highlights:

India, June 30, 2024: Welcure Drugs & Pharmaceuticals Limited (BSE: 524661), has announced to the Bombay Stock Exchange that company has won two fresh export sourcing assignments worth Rs. 856 million (Rs. 85.6 crore) from Giant Exim and Ravina International. The order in addition to recently securing Rs. 517 crore Global Sourcing Mandate with Thailand based Fortune Sagar Impex Company Ltd on 18 June 2025. The Company remains focused on expanding its fee-based export portfolio while maintaining its debt-free capital structure.

On 30^th June 2025, company has received Rs. 428 million (Rs. 42.8 crore) mandate from each, Giant Exim and Ravina International for procurement & consolidation of mycorrhizal inoculant (EXW). The orders will contribute fee-based revenue, with no inventory or logistics risk to the Company. Commission income will be recognised on dispatch of each lot and is expected to enhance margins in the current quarter.

Additionally, the company is in advanced discussions with additional international buyers for similar export sourcing mandates and expects to conclude further orders worth Rs. 200 Million or more within the ongoing quarter, subject to customary commercial formalities.

On 18 June 2025, company announced that it has executed a definitive mandate with Thailand-based Fortune Sagar Impex Company Limited for third-party sourcing and procurement services. The mandate, valued at Rs. 517 crore, is structured under an Ex-Works model and represents a significant milestone in Welcure’s service-led growth strategy. As per the mandate, Welcure Drugs & Pharmaceuticals Ltd will engage in sourcing and procurement of multiple finished-dosage SKUs. Built on fee-based model, the company will earn fixed 5% commission on the cost of goods. The estimated service income of Rs. 25.85 crore is expected for FY 2025–26, substantially adding to Welcure’s revenue. The mandate enhances Welcure’s fee-based portfolio without incremental balance-sheet exposure, making this a high-margin growth opportunity for the company.

The Rs.517 crore mandate involves execution scheduled on a call-off basis with the mobilisation of the initial lot targeted immediately upon fulfilment of the customary prefunding milestones. The engagement is set to conclude by September 30, 2026. The buyer, Fortune Sagar Impex Company Limited, Thailand, will be in-charge of responsibilities related to packaging, labelling, containerisation, insurance, freight and all destination-country regulatory clearances. The transaction is not a related-party arrangement and involves no promoter or group entity interest. This sourcing mandate enables Welcure to scale its fee-based offerings globally and reinforce its positioning as a reliable partner for international pharmaceutical procurement.

Recently, the company conducted a Postal Ballot via remote e-voting from May 16 to June 14, 2025, seeking shareholder approval for appointment of Mr. Chintan Didawala Ganpat as Managing Director for a 5-year tenure. In the same meeting, resolution was passed for increasing the authorized share capital of the company—from Rs. 116 crore to Rs. 186 crore (i.e., 18.6 crore equity shares of Rs. 10 each).

For the financial year that ended on March 31, 2025, company reported Rs 26.45 crores net income with net profit of Rs 2.17 crores.

About Welcure Drugs & Pharmaceuticals Ltd:

Incorporated in 1992, Welcure Drugs & Pharmaceuticals Ltd is an established pharmaceutical company in India, engaged in the manufacture and trade of a wide range of healthcare formulations. With a focus on quality, compliance, and global integration, Welcure continues to expand its presence in both domestic and international markets.

(Disclosures: At the time of writing this article, author, his clients & dependent family members may have positions in the stocks mentioned above. The author, his firm, his clients or any of his dependent family members may make purchases or sale of the securities mentioned in website. Author may have positions in above stocks so have vested interest obviously in their going up or down as the case may be.

Disclaimer: Investing in any equity is risky. Our recommendations are based on reliable & authenticated sources believed to be true & correct, and also is technical analysis based on & conceived from charts. Investors should take their own decisions. We assume no responsibility for any transactions undertaken by them. The author won't be liable or responsible for any legal or financial losses made by anybody. Investors must take advice from their financial advisors before investing in any stocks.)